Connection

Anders Sönnerborg to Humans

This is a "connection" page, showing publications Anders Sönnerborg has written about Humans.
Connection Strength

0.123
  1. [Future testing for SARS-CoV-2: not only more but smarter]. Lakartidningen. 2020 11 26; 117.
    View in: PubMed
    Score: 0.007
  2. [Bats and humans]. Lakartidningen. 2020 04 29; 117.
    View in: PubMed
    Score: 0.007
  3. A viral genome wide association study and genotypic resistance testing in patients failing first line antiretroviral therapy in the first large countrywide Ethiopian HIV cohort. BMC Infect Dis. 2019 Jul 01; 19(1):569.
    View in: PubMed
    Score: 0.007
  4. Baseline predictors of antiretroviral treatment failure and lost to follow up in a multicenter countrywide HIV-1 cohort study in Ethiopia. PLoS One. 2018; 13(7):e0200505.
    View in: PubMed
    Score: 0.006
  5. Pretreatment drug resistance in a large countrywide Ethiopian HIV-1C cohort: a comparison of Sanger and high-throughput sequencing. Sci Rep. 2018 05 15; 8(1):7556.
    View in: PubMed
    Score: 0.006
  6. Increase in transmitted drug resistance in migrants from sub-Saharan Africa diagnosed with HIV-1 in Sweden. AIDS. 2018 04 24; 32(7):877-884.
    View in: PubMed
    Score: 0.006
  7. Ex-vivo antiretroviral potency of newer integrase strand transfer inhibitors cabotegravir and bictegravir in HIV type 1 non-B subtypes. AIDS. 2018 02 20; 32(4):469-476.
    View in: PubMed
    Score: 0.006
  8. Prediction of coreceptor usage by five bioinformatics tools in a large Ethiopian HIV-1 subtype C cohort. PLoS One. 2017; 12(8):e0182384.
    View in: PubMed
    Score: 0.006
  9. Recent increased identification and transmission of HIV-1 unique recombinant forms in Sweden. Sci Rep. 2017 07 25; 7(1):6371.
    View in: PubMed
    Score: 0.006
  10. Effect of therapy switch on time to second-line antiretroviral treatment failure in HIV-infected patients. PLoS One. 2017; 12(7):e0180140.
    View in: PubMed
    Score: 0.006
  11. Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy. PLoS One. 2017; 12(6):e0178942.
    View in: PubMed
    Score: 0.006
  12. Assessing cervical intraepithelial neoplasia as an indicator disease for HIV in a low endemic setting: a population-based register study. BJOG. 2017 Oct; 124(11):1680-1687.
    View in: PubMed
    Score: 0.006
  13. Monophylogenetic HIV-1C epidemic in Ethiopia is dominated by CCR5-tropic viruses-an analysis of a prospective country-wide cohort. BMC Infect Dis. 2017 01 06; 17(1):37.
    View in: PubMed
    Score: 0.006
  14. Selection of drug-resistant HIV-1 during the early phase of viral decay is uncommon in treatment-naïve patients initiated on a three- or four-drug antiretroviral regimen including lamivudine. J Med Virol. 2009 Jan; 81(1):1-8.
    View in: PubMed
    Score: 0.003
  15. Coronavirus helicases: attractive and unique targets of antiviral drug-development and therapeutic patents. Expert Opin Ther Pat. 2021 Apr; 31(4):339-350.
    View in: PubMed
    Score: 0.002
  16. Utility of Proteomics in Emerging and Re-Emerging Infectious Diseases Caused by RNA Viruses. J Proteome Res. 2020 11 06; 19(11):4259-4274.
    View in: PubMed
    Score: 0.002
  17. Infectivity of SARS-CoV-2: there Is Something More than D614G? J Neuroimmune Pharmacol. 2020 12; 15(4):574-577.
    View in: PubMed
    Score: 0.002
  18. Tocilizumab shortens time on mechanical ventilation and length of hospital stay in patients with severe COVID-19: a retrospective cohort study. J Intern Med. 2021 03; 289(3):434-436.
    View in: PubMed
    Score: 0.002
  19. Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. Cell. 2020 10 01; 183(1):158-168.e14.
    View in: PubMed
    Score: 0.002
  20. Lakartidningen. 2020 03 23; 117.
    View in: PubMed
    Score: 0.002
  21. MiDRMpol: A High-Throughput Multiplexed Amplicon Sequencing Workflow to Quantify HIV-1 Drug Resistance Mutations against Protease, Reverse Transcriptase, and Integrase Inhibitors. Viruses. 2019 08 30; 11(9).
    View in: PubMed
    Score: 0.002
  22. Challenges in modelling the proportion of undiagnosed HIV infections in Sweden. Euro Surveill. 2019 Apr; 24(14).
    View in: PubMed
    Score: 0.002
  23. Antiretroviral potency of 4'-ethnyl-2'-fluoro-2'-deoxyadenosine, tenofovir alafenamide and second-generation NNRTIs across diverse HIV-1 subtypes. J Antimicrob Chemother. 2018 10 01; 73(10):2721-2728.
    View in: PubMed
    Score: 0.002
  24. Suppressive antiretroviral therapy associates with effective treatment of high-grade cervical intraepithelial neoplasia. AIDS. 2018 07 17; 32(11):1475-1484.
    View in: PubMed
    Score: 0.002
  25. Limited immune surveillance in lymphoid tissue by cytolytic CD4+ T cells during health and HIV disease. PLoS Pathog. 2018 04; 14(4):e1006973.
    View in: PubMed
    Score: 0.002
  26. Effect of dolutegravir in combination with Nucleoside Reverse Transcriptase Inhibitors (NRTIs) on people living with HIV who have pre-existing NRTI mutations. Int J Antimicrob Agents. 2018 May; 51(5):733-738.
    View in: PubMed
    Score: 0.002
  27. Prophylaxis and treatment of HIV-1 infection in pregnancy - Swedish Recommendations 2017. Infect Dis (Lond). 2018 07; 50(7):495-506.
    View in: PubMed
    Score: 0.002
  28. Human Immunodeficiency Virus Type-1 Elite Controllers Maintain Low Co-Expression of Inhibitory Receptors on CD4+ T Cells. Front Immunol. 2018; 9:19.
    View in: PubMed
    Score: 0.002
  29. Temporal trends of transmitted HIV drug resistance in a multinational seroconversion cohort. AIDS. 2018 Jan 14; 32(2):161-169.
    View in: PubMed
    Score: 0.002
  30. PhyloGeoTool: interactively exploring large phylogenies in an epidemiological context. Bioinformatics. 2017 Dec 15; 33(24):3993-3995.
    View in: PubMed
    Score: 0.001
  31. Transcriptomics and Targeted Proteomics Analysis to Gain Insights Into the Immune-control Mechanisms of HIV-1 Infected Elite Controllers. EBioMedicine. 2018 Jan; 27:40-50.
    View in: PubMed
    Score: 0.001
  32. Indinavir in cerebrospinal fluid of HIV-1-infected patients. Lancet. 1997 Dec 20-27; 350(9094):1823.
    View in: PubMed
    Score: 0.001
  33. Evaluating the Impact of Functional Genetic Variation on HIV-1 Control. J Infect Dis. 2017 11 27; 216(9):1063-1069.
    View in: PubMed
    Score: 0.001
  34. Richer gut microbiota with distinct metabolic profile in HIV infected Elite Controllers. Sci Rep. 2017 07 24; 7(1):6269.
    View in: PubMed
    Score: 0.001
  35. A high rate of HIV-1 acquisition post immigration among migrants in Sweden determined by a CD4 T-cell decline trajectory model. HIV Med. 2017 10; 18(9):677-684.
    View in: PubMed
    Score: 0.001
  36. Quantitative humoral profiling of the HIV-1 proteome in elite controllers and patients with very long-term efficient antiretroviral therapy. Sci Rep. 2017 04 06; 7(1):666.
    View in: PubMed
    Score: 0.001
  37. Letter to the editor: Pre-exposure prophylaxis for HIV in Europe: The need for resistance surveillance. Euro Surveill. 2017 03 16; 22(11).
    View in: PubMed
    Score: 0.001
  38. Perturbed CD8+ T cell TIGIT/CD226/PVR axis despite early initiation of antiretroviral treatment in HIV infected individuals. Sci Rep. 2017 01 13; 7:40354.
    View in: PubMed
    Score: 0.001
  39. Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe. BMC Infect Dis. 2014 Jul 21; 14:407.
    View in: PubMed
    Score: 0.001
  40. Two-year biochemical, virological, and histological follow-up in patients with chronic hepatitis C responding in a sustained fashion to interferon alfa-2b treatment. Hepatology. 1995 Apr; 21(4):918-22.
    View in: PubMed
    Score: 0.000
  41. Human immunodeficiency virus infection of the brain. II. Detection of intrathecally synthesized antibodies by enzyme linked immunosorbent assay and imprint immunofixation. J Neurol Sci. 1988 Oct; 87(1):37-48.
    View in: PubMed
    Score: 0.000
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.